Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors

Main Who May Qualify: - diagnosed by tissue sample (biopsy-confirmed), unresectable, locally advanced or metastatic solid tumors that are known to express Nectin-4 - Prior systemic treatment for locally advanced or metastatic disease, yet no therapy with demonstrated clinical benefit for the tumor type is available. - Measurable disease according to RECIST 1.1. - Archival tumor tissue obtained within 4 months of screening and since the last anticancer therapy prior to the study or agree to undergo a tumor biopsy at baseline. - your organs (liver, kidneys, etc.) are working well enough based on blood tests and hematological function. Main Who Should NOT Join This Trial: - Known or suspected brain metastases. - Participants with an active infection, Any other infection requiring systemic treatment or latent infection. - Participants with clinically significant comorbidity(s). - History of treatment for, or suspicion or confirmed interstitial lung disease (ILD) at baseline. - Condition being treated with systemic corticosteroids or immunosuppressive therapy during IPH4502 treatment. - Thromboembolic event requiring anticoagulation therapy ≤14 days prior to the first dose of IPH4502. - Clinically significant cardiovascular disease and/or cardiac repolarization abnormality. - Participants with symptomatic heart failure, Acute coronary syndromes - Participant is receiving or has received anticancer therapy prior to enrolment that may have impact on the assessment of IPH4502. - Major surgery ≤28 days and minor surgery ≤7 days prior to first dose of IPH4502 or 6 months for coronary artery bypass surgery. - Concomitant medications or vaccines : Live-attenuated vaccines ≤ 6 weeks prior to first dose of IPH4502; systemic corticosteroids or other immunosuppressive agents within 14 days prior to the first dose of IPH4502; systemic use of moderate or strong CYP 3A4 inhibitors; systemic use of moderate or strong CYP 3A4 inducers. Always talk to your doctor about whether this trial is right for you.